Condition
Uterine Cervix Cancer
Total Trials
5
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06331468Phase 2RecruitingPrimary
Hypofractionated Radiochemotherapy
NCT05462951Active Not RecruitingPrimary
Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer
NCT05022511Not ApplicableCompleted
Three Birds With One Stone
NCT03296566Not ApplicableCompleted
The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams
NCT02363829Phase 1CompletedPrimary
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Showing all 5 trials